At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Posterolateral Fusionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion
In Brief
A clinical study evaluating Posterolateral Fusion for Degenerative Changes and 2 related conditions. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented posterolateral spine fusion, as compared to local autograft.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDegenerative Changes, Stenosis, Spondylosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedDec 2013
Primary CompletionJul 2015
Study CompletionMay 2017
TodayJul 2026
First PostedDec 23, 2013
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2015
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.5 years ago
Interventions
Posterolateral Fusionprocedure